Emergent BioSolutions Inc. (EBS) Form 8-K — Jun 29, 2026
$EBSForm 8-KItems 1.01, 7.01, 9.01Filed Jun 29, 2026, 11:14 AM ET0001367644-26-000068Original filing
Emergent BioSolutions has secured a $52.7 million contract modification from the U.S. Department of Health and Human Services' Administration for Strategic Preparedness and Response (ASPR). The modification exercises Option Year 7 of the company's existing 10-year contract to supply ACAM2000, a live vaccinia vaccine for smallpox and mpox, with deliveries expected to begin in June 2026 and conclude in December 2026.
Key figures
- Deal Value Usd
- 52700000
- Contract number
- 75A50119C00071
- Contract option year
- Option Year 7
Price after filing
1 day: +5.0%7 days: +2.5%30 days: -8.4%
Close on the filing date to close N calendar days later (from $7.98). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.